ImmuPharma PLC (LSE:IMM) has confirmed the exercise of 2,500,000 warrants over New Ordinary Shares, raising £125,000 in capital. The newly issued shares, representing 0.50% of the company’s enlarged share capital, will be admitted to trading on the AIM market of the London Stock Exchange.
Following this transaction, ImmuPharma’s total issued share capital will consist of 502,223,932 Ordinary Shares.
About ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutics. Its portfolio includes innovative peptide treatments targeting autoimmune diseases and anti-infective applications.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply